NDA 209661 · Duchesnay
Bonjesta
Doxylamine Succinate, Pyridoxine Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Oct 31, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Nov 7, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
18
5 Phase 3, 0 recruiting
FAERS reports
153
71 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 25, 2025.
BONJESTA is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Limitations of Use BONJESTA has not been studied in women with hyperemesis gravidarum. BONJESTA is a fixed dose combination drug product of 20 mg doxylamine succinate, an antihistamine, and 20 mg pyridoxine hydrochloride, a Vitamin B 6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. ( 1 )
Mechanism: The mechanism of action of BONJESTA is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BONJESTA · DOXYLAMINE SUCCINATE 20MG; PYRIDOXINE HYDROCHLORIDE 20MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Doxylamine" as an intervention, any sponsor and status, largest first.
- Effectiveness of Acupuncture and Doxylamine/Pyridoxine for Moderate to Severe Nausea and Vomiting in PregnancyPivotal-lookingCompleted
Xiaoke WuAcademic, hospital or other
NCT04401384 · 352 participants · Start Jun 21, 2020 · Primary completion Jun 23, 2021
Drug: Diclectin; Diclectin placebo · For: Nausea and Vomiting of Pregnancy
Sites: Harbin, China; Hegang, China; Jiamusi, China · 13 sites in all
- The Efficacy Of Diclectin® For Nausea And Vomiting Of PregnancyPivotal-lookingCompleted
Duchesnay Inc.Industry
NCT00614445 · 280 participants · Start Jan 2008 · Primary completion Jul 2009
Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg; Placebo · For: Nausea and Vomiting of Pregnancy
Sites: Washington D.C., District of Columbia; Bethesda, Maryland; Pittsburgh, Pennsylvania · 7 sites in all
- The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant AdolescentsPivotal-lookingSuspended
Duchesnay Inc.Industry
NCT05289557 · 274 participants (planned) · Start May 1, 2022 · Primary completion Dec 2027
Drug: Bonjesta; Placebo · For: Morning Sickness
Sites: Burbank, California; Hialeah, Florida; Miami, Florida · 10 sites in all
- A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With RobitussinPivotal-lookingCompleted
HALEONIndustry
NCT06716645 · 244 participants · Start Dec 4, 2024 · Primary completion Feb 14, 2025
Drug: Robitussin Maximum Strength Cough and Chest Congestion DM; Robitussin Maximum Strength Cough and Chest Congestion DM and 1 more · For: Common Cold; Cough
Sites: New York, New York
National Cancer Institute (NCI)NIH
NCT02858310 · 224 participants · Start Jan 27, 2017 · Primary completion Jul 2, 2025
Drug: E7 TCR cells; Aldesleukin and 15 more · For: Papillomavirus Infections; Cervical Intraepithelial Neoplasia; Carcinoma In Situ and 2 more
Sites: Bethesda, Maryland; New Brunswick, New Jersey
- Effectiveness and Safety of the of Guaifenesin, Doxylamine Succinate and Hydrochloride Etafedrine Syrup in Improvement of Symptoms Resulting From Acute Respiratory Infections.Pivotal-lookingStatus unknown
Azidus BrasilIndustry
NCT00857987 · 174 participants (planned) · Start Apr 2010 · Primary completion Oct 2011
Drug: EMS Expectorant · For: Upper Airway Infections
Sites: Valinhos, Brazil
- A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant AdolescentsPivotal-lookingTerminated
Duchesnay Inc.Industry
NCT02045901 · 131 participants · Start Feb 2014 · Primary completion Mar 31, 2017
Drug: Diclegis; Placebo (Sugar Pill) · For: Morning Sickness
Sites: Tucson, Arizona; Los Angeles, California; Norwalk, California · 8 sites in all
- Pre-emptive Treatment of Severe Nausea and Vomiting of PregnancyPivotal-lookingCompleted
The Hospital for Sick ChildrenAcademic, hospital or other
NCT00293644 · 76 participants · Start Feb 2006 · Primary completion Jun 2012
Drug: Diclectin® · For: Hyperemesis Gravidarum; Pregnancy
Sites: Toronto, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- maternal exposure during pregnancy25
- nausea17
- drug ineffective16
- exposure during pregnancy16
- off label use13
- abortion spontaneous12
- product use in unapproved indication10
- serotonin syndrome10
- somnolence10
- vomiting10
- drug ineffective for unapproved indication9
- foetal exposure during pregnancy8
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 22 |
| 2019 | 28 |
| 2020 | 12 |
| 2021 | 16 |
| 2022 | 21 |
| 2023 | 16 |
| 2024 | 15 |
| 2025 | 13 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bonjesta (Doxylamine Succinate/Vit B6)
2024 spending
$47K
Beneficiaries
39
70 claims
Per beneficiary
$1,212
$11.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $31,655 |
| 2021 | $45,580 |
| 2022 | $28,004 |
| 2023 | $39,236 |
| 2024 | $47,257 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, et al. · Lancet 2022 · Network Meta-Analysis, Systematic Review
- Standardized Extract of Valeriana officinalis Improves Overall Sleep Quality in Human Subjects with Sleep Complaints: A Randomized, Double-Blind, Placebo-Controlled, Clinical Study.
Chandra Shekhar H, Joshua L, Thomas JV · Adv Ther 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review.
McParlin C, O'Donnell A, Robson SC, et al. · JAMA 2016 · Research Support, Non-U.S. Gov't, Systematic Review
- [Insomnia in the context of affective disorders].
Mendelevich VD, Mendelevich EG · Zh Nevrol Psikhiatr Im S S Korsakova 2023 · English Abstract, Network Meta-Analysis
- Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2ߙ×ߙ2 Factorial Trial.
Wu XK, Gao JS, Ma HL, et al. · Ann Intern Med 2023 · Randomized Controlled Trial, Multicenter Study
- Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review and economic assessment.
O'Donnell A, McParlin C, Robson SC, et al. · Health Technol Assess 2016 · Systematic Review
Sponsor: Duchesnay
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.